Verona Pharma plc (VRNA)

14,79 -0,16 (-1,07%) Alla chiusura: 04:00PM EDT

Verona Pharma plc

3 More London Riverside
London SE1 2RE
United Kingdom
44 20 3283 4200
https://www.veronapharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 79

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. David S. Zaccardelli Pharm.D.	President, CEO & Executive Director	1,27M	N/D	1964
Mr. Mark W. Hahn	Chief Financial Officer	858,29k	N/D	1963
Dr. Kathleen A. Rickard M.D.	Chief Medical Officer	650,83k	N/D	1958
Mr. Andrew Fisher	General Counsel	N/D	N/D	1970
Ms. Victoria Stewart	Director of Communications	N/D	N/D	N/D
Mr. Matthew Casbon	VP of Sales, Marketing & Training	N/D	N/D	N/D
Ms. Ostra Jewell	Senior Vice President of Human Resources	N/D	N/D	N/D
Dr. Tara Rheault M.P.H., Ph.D.	Chief Development Officer	N/D	N/D	1977
Mr. Christopher Martin	Chief Commercial Officer	N/D	N/D	N/D
Ms. Caroline Diaz	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Verona Pharma plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.